Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Michael Gulrajani"'
Autor:
Michael Gulrajani, Tracy Clevenger, Jean Cheung, Fanny Krantz, Cynthia Nguyen, Miranda Luarca, Cecile Krejsa, Wayne P. Rothbaum, Todd Covey
Publikováno v:
HemaSphere, Vol 7, p e41702a0 (2023)
Externí odkaz:
https://doaj.org/article/259097e869d94146bf92ec05ff2b12da
Autor:
Tracy Clevenger, Jean Cheung, Fanny Krantz, Michael Gulrajani, Cynthia Nguyen, Miranda Luarca, Cecile Krejsa, Wayne P. Rothbaum, Todd Covey
Publikováno v:
HemaSphere, Vol 7, p e281417f (2023)
Externí odkaz:
https://doaj.org/article/3f79b1bcc9b1453983bdc7875797908b
Autor:
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Externí odkaz:
https://doaj.org/article/885fb92964b3445a99b5a10f0adb8206
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e8b6c08b1eaaf021847b37b47834a
https://doi.org/10.1158/2159-8290.c.6547811.v1
https://doi.org/10.1158/2159-8290.c.6547811.v1
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Figure S1 shows immunoglobulin A, B, and M levels in treated patients over time Figure S2 shows investigator-assessed progression-free survival by CLL-IPI score and presence or absence of complex karyotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ecbd95eea50dde789f03387b686897
https://doi.org/10.1158/2159-8290.22535279.v1
https://doi.org/10.1158/2159-8290.22535279.v1
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the antitumor effects of acalabrutinib treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e3ca1183f3e1691c0fae26104477a98
https://doi.org/10.1158/1078-0432.c.6525228.v1
https://doi.org/10.1158/1078-0432.c.6525228.v1
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Table S1. Kinase selectivity of acalabrutinib as assessed by DiscoveRX KinomeScan screening.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87cd29d20b722cbec12775285af50743
https://doi.org/10.1158/1078-0432.22462842
https://doi.org/10.1158/1078-0432.22462842
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Figure S5: Acalabrutinib demonstrates similar changes in proliferation and tumor burden in the CLL xenograft mouse model as ibrutinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c6b24397ba4d6b61ecbea462928663
https://doi.org/10.1158/1078-0432.22462839
https://doi.org/10.1158/1078-0432.22462839
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Figure S1: Acalabrutinib is a more potent BCR-inhibitor than ibrutinib in vivo at 1mg/kg and 3mg/kg. Supplementary Figure S2: In vivo gating strategy for murine cells. Supplementary Figure S3: In vivo acalabrutinib treatment inhibits BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e9dec56789480c721bd888084a7d11
https://doi.org/10.1158/1078-0432.22462836.v1
https://doi.org/10.1158/1078-0432.22462836.v1
Autor:
Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd
Publikováno v:
Blood. 140:5936-5938
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b73acaafb77c2acc9a62fe18d9c628a
https://doi.org/10.1182/blood-2022-159568
https://doi.org/10.1182/blood-2022-159568